Drugs that contain Mobocertinib Succinate
1. Drug name - EXKIVITY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10227342 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(12 years from now) | |
| US9796712 | TAKEDA PHARMS USA | Heteroaryl compounds for kinase inhibition |
May, 2035
(12 years from now) | |
| CN106559991B | TAKEDA PHARMS USA | Heteroaryl Compounds For Kinase Inhibition |
May, 2035
(12 years from now) | |
| CN106559991A | TAKEDA PHARMS USA | Heteroaryl Compounds For Kinase Inhibition |
May, 2035
(12 years from now) | |
| EP3409669B1 | TAKEDA PHARMS USA | Heteroaryl Compounds For Kinase Inhibition |
May, 2035
(12 years from now) | |
| EP3157916B1 | TAKEDA PHARMS USA | Heteroaryl Compounds For Kinase Inhibition |
May, 2035
(12 years from now) | |
| EP3157916A4 | TAKEDA PHARMS USA | Heteroaryl Compounds For Kinase Inhibition |
May, 2035
(12 years from now) | |
| EP3409669A1 | TAKEDA PHARMS USA | Heteroaryl Compounds For Kinase Inhibition |
May, 2035
(12 years from now) | |
| EP3157916A1 | TAKEDA PHARMS USA | Heteroaryl Compounds For Kinase Inhibition |
May, 2035
(12 years from now) | |
Treatment: NA
Dosage: CAPSULE;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.